Market closedNon-fractional
Longboard Pharmaceuticals/LBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Ticker
LBPH
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
La Jolla, United States
Employees
50
Website
www.longboardpharma.com
LBPH Metrics
BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$2.19
EPS
1.27
Beta
-
Dividend rate
Price and volume
Market cap
$1.4B
Beta
1.27
Financial strength
Current ratio
31.433
Quick ratio
31.2
Long term debt to equity
1.169
Total debt to equity
1.269
Management effectiveness
Return on assets (TTM)
-19.30%
Return on equity (TTM)
-30.04%
Valuation
Price to book
4.43
Price to tangible book (TTM)
4.43
Price to free cash flow (TTM)
-17.897
Growth
Earnings per share change (TTM)
-14.00%
3-year earnings per share growth (CAGR)
-20.42%
What the Analysts think about LBPH
Analyst Ratings
Majority rating from 9 analysts.
LBPH Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
-0.67%
Profit margin
0.00%
NaN%
LBPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.65
-$0.55
-$0.62
-$0.42
-
Expected
-$0.60
-$0.70
-$0.60
-$0.49
-$0.44
Surprise
9.11%
-21.87%
3.80%
-13.63%
-
LBPH News
AllArticlesVideos
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
Business Wire·4 weeks ago
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Business Wire·2 months ago
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Longboard Pharmaceuticals stock?
Longboard Pharmaceuticals (LBPH) has a market cap of $1.4B as of July 27, 2024.
What is the P/E ratio for Longboard Pharmaceuticals stock?
The price to earnings (P/E) ratio for Longboard Pharmaceuticals (LBPH) stock is 0 as of July 27, 2024.
Does Longboard Pharmaceuticals stock pay dividends?
No, Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Longboard Pharmaceuticals dividend payment date?
Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Longboard Pharmaceuticals?
Longboard Pharmaceuticals (LBPH) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Longboard Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.